SCHEMBL3635646

SCHEMBL3635646

O=c1ccc(N2CCNCC2)n[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.47
HRH3 Q9Y5N1 4/20 0.45
OGA O60502 2/20 0.45
HTR3E A5X5Y0 3/20 0.45
HTR3B O95264 3/20 0.45
HTR3A P46098 3/20 0.45
HTR3D Q70Z44 3/20 0.45
HTR3C Q8WXA8 3/20 0.45
HTR2C P28335 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
CYP1A2 P05177 1/20 0.45
ADRB1 P08588 1/20 0.45
CYP3A4 P08684 1/20 0.45
HTR1A P08908 1/20 0.45
MAPK1 P28482 1/20 0.45
SLC6A4 P31645 1/20 0.45
HTR7 P34969 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3095897 0.98 BPTF (0.46) BPTFHRH3OGAHTR3EHTR3B
SCHEMBL31514107 0.85 HRH3 (0.48) HRH3OGAALDH1A1KDM4ECYP1A2
SCHEMBL29214647 0.80 GAA (0.54) HRH3OGAALDH1A1CYP1A2MAPK1
SCHEMBL10072964 0.80 OGA (0.50) HRH3OGAHTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL4941484 0.79 SMO (0.52) HRH3OGAALDH1A1KDM4EHTT
SCHEMBL15548336 0.77 HRH3 (0.54) HRH3OGAALDH1A1HTT
SCHEMBL4890873 0.74 LMNA (0.55) HRH3OGAKDM4EUSP2HTT
SCHEMBL31514125 0.73 OGA (0.41) HRH3OGAALDH1A1KDM4ECYP1A2
SCHEMBL9214671 0.72 HRH3 (0.46) HRH3OGA
SCHEMBL1559213 0.71 PLD1 (0.48) BPTFHRH3HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-10-06 US disclosed
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
EP-2754660-B1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-11-02 EP disclosed
US-9284300-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-8927540-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2015-01-06 US disclosed
US-8927540-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2015-01-06 US disclosed
US-8580781-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2013-11-12 US disclosed
US-8580781-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2013-11-12 US disclosed
US-20130184261-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20130184260-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20130184260-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20130184261-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20100234354-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
US-20100234354-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
EP-2164843-A1 PYRIDAZINONE DERIVATES Merck Patent GmbH (DE) 2010-03-24 EP disclosed
WO-2009006959-A1 PYRIDAZINONE DERIVATES MERCK PATENT GMBH (DE) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184261-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 BPTF 3809/4885HRH3 1069/4885OGA 4623/4885
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 BPTF 3522/4885HRH3 2320/4885OGA 284/4885
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION GCGR, STUB1, GID4 BPTF 3293/4885HRH3 1232/4885OGA 225/4885
US-20130184260-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 BPTF 3937/4885HRH3 1014/4885OGA 4680/4885
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 BPTF 3937/4885HRH3 1014/4885OGA 4680/4885
US-20100234354-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 BPTF 3974/4885HRH3 925/4885OGA 4667/4885
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 BPTF 3522/4885HRH3 2320/4885OGA 284/4885
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation GID4, RNF5, UBE3C BPTF 3579/4885HRH3 2725/4885OGA 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.